Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects
Nagy A. Farid(Eli Lilly (United States)), Kenneth J. Winters(Eli Lilly (United States)), Daniel E. Salazar(Daiichi Sankyo (United States)), Christopher S. Konkoy(Eli Lilly (United States)), John T. Brandt(Universitätsklinikum Würzburg), Joseph A. Jakubowski(Indiana Biosciences Research Institute), C. Steven Ernest(Metrum Research Group (United States)), Ying G. Li(Eli Lilly (United States)), David S. Small(Eli Lilly (United States)), Christopher D. Payne(Eli Lilly (United States))
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
November 24, 2008
Cited by 87
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617